Two new drugs from Changchun Hi-Tech (000661.SZ) subsidiary added to the national medical insurance catalogue

Zhitongcaijing · 2d ago

Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) announced that according to the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2025)” issued by the National Medical Security Administration and the Ministry of Human Resources and Social Security, Jinsaizeng (now commonly known as “Jinsai Pharmaceutical”) independently developed by the company's holding subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (now commonly known as “Jinpei Growth Hormone Injection”) and the cooperative introduction of Meshya (generic name “methyldiprogesterone acetate oral suspension”) have all been newly included in the national health insurance catalogue.